Filing Flows › Assembly Biosciences (ASMB) › Q1 2026 › vs Q3 2025
Assembly Biosciences (ASMB) Q1 2026 vs Q3 2025 (quarter over quarter)
Assembly Biosciences's revenue fell $34.3M (-81%) from $42.5M in Q3 2025 to $8.2M in Q1 2026.
Assembly Biosciences, Q1 2026: revenue $8.2M (-13% year over year), operating margin -138.4%, net loss $9.1M, operating cash flow −$22.1M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.2M | $42.5M | −$34.3M | -81% |
| Other income, net | $2.3M | $2.3M | $0 | 0% |
| Net loss | $9.1M | −$22.1M | $31.2M | — |
| Costs & expenses | $19.6M | $44.8M | −$25.2M | -56% |
| Operating costs | $19.6M | $22.7M | −$3.1M | -14% |
| Research & development | $14.9M | $17.2M | −$2.4M | -14% |
| General & admin | $4.7M | $5.4M | −$737K | -14% |
| Operating cash sources | $23.2M | −$12.7M | $36.0M | — |
| Depreciation & amortization | $26K | $32K | −$6K | -19% |
| Share-based compensation | $1.1M | $1.5M | −$345K | -24% |
| Cash used in operations | $22.1M | −$14.2M | $36.3M | — |
| Net loss absorbed | $9.1M | −$22.1M | $31.2M | — |
| Working capital & other | $14.2M | $9.3M | $4.8M | +52% |
Questions
How much did Assembly Biosciences's revenue grow quarter over quarter in Q1 2026?
Assembly Biosciences's revenue fell $34.3M (-81%) from $42.5M in Q3 2025 to $8.2M in Q1 2026.